Xeris Biopharma Holdings, Inc. Insider Trading

XERS

Last 12 months

Insiders sold $5.82M and bought nothing on the open market.

83% of the selling was scheduled in advance under 10b5-1 plans. Director John Johnson sold 978K on Dec 19, 2025, 16% of their stake, outside a plan. The last open-market buy by an executive or director was in Jun 2025.

Net open-market

−$5.82M

0 buys · 34 sales

Under a 10b5-1 plan

83%

of the value sold

Insiders who bought / sold

0 / 9

executives and directors

Last open-market buy

Jun 2025

Jun 13, 2025

Get an email when XERS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Nov 2	Steven Pieper See Remarks	Sold10b5-1 plan	5,000	$10.23	51K	0.4%	Form 4
Nov 2	Beth Hecht See Remarks	Sold10b5-1 plan	25,000	$10.23	256K	2.2%	Form 4
Nov 2	Kevin McCulloch See Remarks	Sold10b5-1 plan	15,000	$10.23	153K	0.9%	Form 4
Oct 1	Steven Pieper See Remarks	Sold10b5-1 plan	5,000	$9.41	47K	0.4%	Form 4
Oct 1	Kevin McCulloch See Remarks	Sold10b5-1 plan	15,000	$9.41	141K	0.9%	Form 4
Oct 1	Beth Hecht See Remarks	Sold10b5-1 plan	16,666	$9.41	157K	1.5%	Form 4
Sep 28	Kevin McCulloch See Remarks	Sold10b5-1 plan	25,000	$10.00	250K	1.5%	Form 4
Sep 1	Kevin McCulloch See Remarks	Sold10b5-1 plan	15,000	$8.49	127K	0.9%	Form 4
Sep 1	Steven Pieper See Remarks	Sold10b5-1 plan	5,000	$8.50	43K	0.4%	Form 4
Sep 1	Beth Hecht See Remarks	Sold10b5-1 plan	16,666	$8.49	141K	1.5%	Form 4
Aug 12	Steven Pieper See Remarks	Sold10b5-1 plan	5,000	$8.50	43K	0.4%	Form 4
Aug 3	Kevin McCulloch See Remarks	Sold10b5-1 plan	15,000	$8.02	120K	0.9%	Form 4
Aug 3	Beth Hecht See Remarks	Sold10b5-1 plan	16,666	$8.01	133K	1.4%	Form 4
Jul 6 – 7	Steven Pieper See Remarks	Sold10b5-1 plan 2 parts	45,000	$8.51 average	383K	3.2%	Form 4
Jul 1	Kevin McCulloch See Remarks	Sold10b5-1 plan	90,000	$8.03	723K	5.0%	Form 4
Jul 1	Beth Hecht See Remarks	Sold10b5-1 plan	16,666	$8.03	134K	1.4%	Form 4
Jun 4	Dawn Halkuff Director	Sold10b5-1 plan	20,000	$6.09	122K	14%	Form 4
Jun 4	Barbara-Jean Anne Bormann-Kennedy Director	Sold10b5-1 plan	16,000	$6.09	97K	9.6%	Form 4
Jun 4	John Johnson Director	Sold10b5-1 plan	15,000	$6.09	91K	2.1%	Form 4
Jun 3	Marla Persky Director	Sold10b5-1 plan	15,500	$5.90	91K	9.0%	Form 4
Jun 1	Beth Hecht See Remarks	Sold10b5-1 plan	16,667	$6.06	101K	1.4%	Form 4
May 1	Beth Hecht See Remarks	Sold10b5-1 plan	16,667	$6.23	104K	1.4%	Form 4
Apr 1	Beth Hecht See Remarks	Sold10b5-1 plan	16,667	$5.99	100K	1.4%	Form 4
Mar 30	James Aloysius Brady Director	Sold10b5-1 plan	10,834	$5.54	60K	11%	Form 4
Mar 2	Beth Hecht See Remarks	Sold10b5-1 plan 2 parts	16,667	$6.24 average	104K	1.3%	Form 4
Feb 2	Beth Hecht See Remarks	Sold10b5-1 plan	16,667	$7.45	124K	1.3%	Form 4
Jan 8	Kevin McCulloch See Remarks	Sold10b5-1 plan	15,000	$8.00	120K	0.9%	Form 4
Jan 5	John Patrick Shannon Jr See Remarks	Sold10b5-1 plan	24,907	$7.08	176K	0.9%	Form 4
Jan 2	Beth Hecht See Remarks	Sold10b5-1 plan	16,667	$7.43	124K	1.3%	Form 4
Dec 19, 2025	John Johnson Director	SoldNo plan	135,400	$7.22	978K	16%	Form 4
Dec 12, 2025	Barbara-Jean Anne Bormann-Kennedy Director	Sold10b5-1 plan	15,000	$7.09	106K	9.5%	Form 4
Dec 1, 2025	Beth Hecht See Remarks	Sold10b5-1 plan	16,667	$7.01	117K	1.2%	Form 4
Nov 13, 2025	John Patrick Shannon Jr See Remarks	Sold10b5-1 plan	23,242	$7.46	173K	0.8%	Form 4
Nov 11, 2025	Beth Hecht See Remarks	Sold10b5-1 plan	16,667	$7.40	123K	1.2%	Form 4
Sep 11, 2025	Marla Persky Director	Sold10b5-1 plan	15,500	$7.72	120K	9.5%	Form 4
Aug 28, 2025	Jeffrey W Sherman Director	SoldNo plan	42,232	$7.92	334K	16%	Form 4
Aug 13, 2025	John Johnson Director	SoldNo plan	107,500	$7.32	787K	11%	Form 4
Aug 12, 2025	Dawn Halkuff Director	SoldNo plan	42,500	$7.28	309K	26%	Form 4
Jun 13, 2025	Kevin McCulloch See Remarks	Bought	25,000	$4.38	110K	1.5%	Form 4
Mar 20, 2025	Beth Hecht See Remarks	SoldNo plan	40,000	$5.43	217K	2.9%	Form 4

Nov 210b5-1 plan
Steven Pieper
See Remarks · sold 5,000 at $10.23
51K
0.4% of stake
Nov 210b5-1 plan
Beth Hecht
See Remarks · sold 25,000 at $10.23
256K
2.2% of stake
Nov 210b5-1 plan
Kevin McCulloch
See Remarks · sold 15,000 at $10.23
153K
0.9% of stake
Oct 110b5-1 plan
Steven Pieper
See Remarks · sold 5,000 at $9.41
47K
0.4% of stake
Oct 110b5-1 plan
Kevin McCulloch
See Remarks · sold 15,000 at $9.41
141K
0.9% of stake
Oct 110b5-1 plan
Beth Hecht
See Remarks · sold 16,666 at $9.41
157K
1.5% of stake
Sep 2810b5-1 plan
Kevin McCulloch
See Remarks · sold 25,000 at $10.00
250K
1.5% of stake
Sep 110b5-1 plan
Kevin McCulloch
See Remarks · sold 15,000 at $8.49
127K
0.9% of stake
Sep 110b5-1 plan
Steven Pieper
See Remarks · sold 5,000 at $8.50
43K
0.4% of stake
Sep 110b5-1 plan
Beth Hecht
See Remarks · sold 16,666 at $8.49
141K
1.5% of stake
Aug 1210b5-1 plan
Steven Pieper
See Remarks · sold 5,000 at $8.50
43K
0.4% of stake
Aug 310b5-1 plan
Kevin McCulloch
See Remarks · sold 15,000 at $8.02
120K
0.9% of stake
Aug 310b5-1 plan
Beth Hecht
See Remarks · sold 16,666 at $8.01
133K
1.4% of stake
Jul 6 – 710b5-1 plan
Steven Pieper
See Remarks · sold 45,000 at avg $8.51
383K
3.2% of stake
Jul 110b5-1 plan
Kevin McCulloch
See Remarks · sold 90,000 at $8.03
723K
5.0% of stake
Jul 110b5-1 plan
Beth Hecht
See Remarks · sold 16,666 at $8.03
134K
1.4% of stake
Jun 410b5-1 plan
Dawn Halkuff
Director · sold 20,000 at $6.09
122K
14% of stake
Jun 410b5-1 plan
Barbara-Jean Anne Bormann-Kennedy
Director · sold 16,000 at $6.09
97K
9.6% of stake
Jun 410b5-1 plan
John Johnson
Director · sold 15,000 at $6.09
91K
2.1% of stake
Jun 310b5-1 plan
Marla Persky
Director · sold 15,500 at $5.90
91K
9.0% of stake
Jun 110b5-1 plan
Beth Hecht
See Remarks · sold 16,667 at $6.06
101K
1.4% of stake
May 110b5-1 plan
Beth Hecht
See Remarks · sold 16,667 at $6.23
104K
1.4% of stake
Apr 110b5-1 plan
Beth Hecht
See Remarks · sold 16,667 at $5.99
100K
1.4% of stake
Mar 3010b5-1 plan
James Aloysius Brady
Director · sold 10,834 at $5.54
60K
11% of stake
Mar 210b5-1 plan
Beth Hecht
See Remarks · sold 16,667 at avg $6.24
104K
1.3% of stake
Feb 210b5-1 plan
Beth Hecht
See Remarks · sold 16,667 at $7.45
124K
1.3% of stake
Jan 810b5-1 plan
Kevin McCulloch
See Remarks · sold 15,000 at $8.00
120K
0.9% of stake
Jan 510b5-1 plan
John Patrick Shannon Jr
See Remarks · sold 24,907 at $7.08
176K
0.9% of stake
Jan 210b5-1 plan
Beth Hecht
See Remarks · sold 16,667 at $7.43
124K
1.3% of stake
Dec 19, 2025No plan
John Johnson
Director · sold 135,400 at $7.22
978K
16% of stake
Dec 12, 202510b5-1 plan
Barbara-Jean Anne Bormann-Kennedy
Director · sold 15,000 at $7.09
106K
9.5% of stake
Dec 1, 202510b5-1 plan
Beth Hecht
See Remarks · sold 16,667 at $7.01
117K
1.2% of stake
Nov 13, 202510b5-1 plan
John Patrick Shannon Jr
See Remarks · sold 23,242 at $7.46
173K
0.8% of stake
Nov 11, 202510b5-1 plan
Beth Hecht
See Remarks · sold 16,667 at $7.40
123K
1.2% of stake
Sep 11, 202510b5-1 plan
Marla Persky
Director · sold 15,500 at $7.72
120K
9.5% of stake
Aug 28, 2025No plan
Jeffrey W Sherman
Director · sold 42,232 at $7.92
334K
16% of stake
Aug 13, 2025No plan
John Johnson
Director · sold 107,500 at $7.32
787K
11% of stake
Aug 12, 2025No plan
Dawn Halkuff
Director · sold 42,500 at $7.28
309K
26% of stake
Jun 13, 2025
Kevin McCulloch
See Remarks · bought 25,000 at $4.38
110K
1.5% of stake
Mar 20, 2025No plan
Beth Hecht
See Remarks · sold 40,000 at $5.43
217K
2.9% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch XERS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with XERS

CompareIntrinsic value

VREOFVireo Growth Inc.

$7.29-2.15%30

ARVNArvinas Inc.

$7.42+4.65%40

EOLSEvolus Inc.

$7.47+1.36%30

AUPHAurinia Pharmaceuticals Inc.

$17.11+3.32%58

MNKDMannKind Corporation

$3.93+5.36%30

LQDALiquidia Corporation

$47.38+12.27%72

IRWDIronwood Pharmaceuticals Inc.

$3.77+7.71%52

RIGLRigel Pharmaceuticals, Inc.

$51.29+4.97%87

Held by ETFs

XERS is in 40 US ETFs. The largest of them, with XERS's weight in each:

Spot a number that looks wrong? Check it in XERS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing XERS

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.